【摘要】 单、复方阿米洛利治疗心力衰竭109例,采用双盲、随机、分层自身及组间对照,疗程两周,分四个组:Ⅰ组阿米洛利5mg加氢氯噻嗪(双氢克尿塞)50mg/日;Ⅱ组阿米洛利5mg加氢氯噻嗪25mg/日;Ⅲ组阿米洛利10mg分2次服;Ⅳ组氨苯蝶啶50mg,每日3次。结果:四个组均有保钾利尿作用,但Ⅰ组利尿作用优于Ⅱ和Ⅲ组.Ⅲ组优于Ⅳ组(P<0.01及P<0.05)。Ⅲ组保钾作用较好,自身前后血钾P<0.05。四个组尿钾排出均较治疗前减少,自身对照P均<0.01。Ⅰ、Ⅱ、Ⅲ组中共7例治疗后室早消失。其中4例原有低钾心电图表现者亦恢复,故认为此药对心力衰竭保钾利尿作用良好。更多还原

【Abstract】 One hundred and nine cases of heart failure were treated with single or compound amiloride by double-blind and randomization for two weeks.Patients were divided into four groups: (1) amiloride 5 mg plus dihydrochlorothiazide 50 mg/day (group Ⅰ), (2) amiloride 5 mg plus dihydrochlorothiazide 25 mg/day (group Ⅱ), (3) amiloride 5 mg b. i. d. (group Ⅲ), (4) triamterene 50 mg t. i. d. (group Ⅳ).Results: Potassium-sparing and diuretic actions were found in all of the four groups, but the diuretic action of group Ⅰ was superior to that of group Ⅱ and group Ⅲ, and group Ⅲ was superior to group Ⅳ (P<O.01 and P<O.05, respectively). Potassium-sparing action in group Ⅰ was the strongest among the 4 groups. Urinary potassium concentrations were significantly decreased among all of the groups. All cases (7) with premature ventricular beats were controlled after treatment. Hypokalemic ECG in 18 cases became normal.Amiloride is a new diuretic. Treatment of heart failure by compound amiloride (amiloride plus dihydrochlorothiazide 50 mg) is satisfactory.更多还原